New hope for High-Risk breast cancer: immunotherapy after standard care
NCT ID NCT07486687
First seen Mar 22, 2026 · Last updated May 23, 2026 · Updated 8 times
Summary
This phase 3 trial tests whether adding the immunotherapy drug pembrolizumab to standard post-surgery treatment can help prevent breast cancer from coming back in people with early-stage triple-negative breast cancer who still have cancer after initial chemo and immunotherapy. About 1,000 adults with stage II or III disease will be randomly assigned to receive either standard care alone or standard care plus pembrolizumab. The study aims to see if the extra treatment improves survival without cancer recurrence.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER STAGE II are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.